• Explore /
  • Poster
  • / Influence of cardiovascular (CV) comorbidities on the selection of hormone deprivation therapy (HDT) in the treatment of metastatic prostate cancer (mPCa).

Influence of cardiovascular (CV) comorbidities on the selection of hormone deprivation therapy (HDT) in the treatment of metastatic prostate cancer (mPCa).

Abstract Poster

Authors

Jan Lehmann

Jan Lehmann

Urologische Gemeinschaftspraxis, Pruener Gang, Kiel, Germany

Jan Lehmann , Markus Flesch , Sebastian Vosgerau , Michael Gedamke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS392)

DOI

10.1200/JCO.2018.36.6_suppl.TPS392

Abstract #

TPS392

Poster Bd #

M12

Abstract Disclosures

Similar Posters

First Author: Bertrand Tombal

First Author: Ye Yuan

First Author: Andreas Eisenhardt

First Author: John Nikitas